Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A2 | P11168 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430614 | 0.90 | SLC2A2 (0.77) | SLC2A2CYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL13341900 | 0.87 | ALDH1A1 (0.61) | SLC2A2CYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL2933100 | 0.84 | SLC2A2 (0.86) | SLC2A2CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL13341887 | 0.82 | SMN1; SMN2 (0.56) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL6686729 | 0.82 | NTRK1 (0.58) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL17719060 | 0.82 | SLC2A2 (1.00) | SLC2A2CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL13341897 | 0.82 | GABRB2 (0.62) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL28232963 | 0.82 | MAPK1 (0.54) | SLC2A2CYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL29870907 | 0.81 | ALDH1A1 (0.85) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL10675936 | 0.81 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | VIVORYON THERAPEUTICS N.V. (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-3750878-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics AG (DE) | 2020-12-16 | — | — | EP | disclosed |
| US-8183377-B2 | Process for the preparation of imidazopyridines | ELDER PHARMACEUTICALS LTD. | 2012-05-22 | — | — | US | disclosed |
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100036129-A1 | PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES | ELDER PHARMACEUTICALS LTD. (IN) | 2010-02-11 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1917263-A1 | PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES | Elder Pharmaceuticals Ltd (IN) | 2008-05-07 | — | — | EP | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2007023504-A1 | PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES | ELDER PHARMACEUTICALS LTD (IN) | 2007-03-01 | — | — | WO | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| EP-1311508-B1 | NOVEL BETA-AMYLOID INHIBITORS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-11-17 | — | — | EP | disclosed |
| EP-1038875-B1 | Imidazopyridine derivatives and process for making them | SYNTHON BV (NL) | 2003-06-04 | — | — | EP | disclosed |
| EP-1311508-A2 | NOVEL BETA-AMYLOID INHIBITORS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2003-05-21 | — | — | EP | disclosed |
| US-6514969-B2 | Alzheimer's diseas, Parkinson disease, Huntington disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-02-04 | — | — | US | disclosed |
| US-20020042420-A1 | Beta-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-11 | — | — | US | disclosed |
| WO-2002014313-A2 | NOVEL BETA-AMYLOID INHIBITORS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-02-21 | — | — | WO | disclosed |
| US-6281360-B1 | REACTING IMIDAZOPYRIDINE COMPOUND WITH GLYOXYLIC ACID | SYNTHON BV (NL) | 2001-08-28 | — | — | US | disclosed |
| EP-1038875-A2 | Imidazopyridine derivatives and process for making them | Synthon B.V. (NL) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | BMP1, DPEP1, MEP1A | SLC2A2 4725/4885CYP1A2 1681/4885CYP2C9 2469/4885 |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | CNR1, CNR2, GABRA5 | SLC2A2 4309/4885CYP1A2 55/4885CYP2C9 262/4885 |
| US-20100036129-A1 | PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES | OTC, ODC1, OGDH | SLC2A2 1958/4885CYP1A2 70/4885CYP2C9 33/4885 |
| US-20020042420-A1 | Beta-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions | HTT, APP, BACE1 | SLC2A2 931/4885CYP1A2 1164/4885CYP2C9 1935/4885 |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | MTNR1B, ADORA2B, ADRA2B | SLC2A2 4317/4885CYP1A2 59/4885CYP2C9 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.